We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Skinbiotherapeutics Plc | LSE:SBTX | London | Ordinary Share | GB00BF33H870 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.025 | 0.14% | 17.375 | 17.25 | 17.50 | 17.375 | 17.25 | 17.25 | 180,461 | 08:26:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 132k | -2.84M | -0.0125 | -13.90 | 39.23M |
Date | Subject | Author | Discuss |
---|---|---|---|
08/12/2024 22:56 | I did say, shouldn’t we be shorting Croda at 10,000, Now 3,700 Be interesting to know who did short it ? The maker perhaps ? | kreature | |
07/12/2024 21:32 | Yeah, i can see why they are doing business here really Glad all that scaling up for manufacturing was ringfenced for here? | putinaire | |
07/12/2024 21:32 | Specific data on the number of failed product launches by Croda Group plc is not publicly available. However, the company has faced challenges in recent years, including a significant decline in profitability and sales. In 2023, Croda reported a 70% drop in pre-tax profit, from £780 million in 2022 to £236.3 million in 2023, and a 19% decrease in sales, attributed to prolonged destocking and a weaker macroeconomic environment. MORNING STAR Additionally, in October 2023, Croda announced cost-cutting measures, such as plant shutdowns and reduced shift patterns, due to lower-than-expected sales in its beauty care business and challenges in the North American market. THE INDEPENDENT While these issues may not directly indicate failed product launches, they suggest difficulties in product performance and market demand. .......... | putinaire | |
07/12/2024 21:27 | What a blag that week No numbers No assurances on cash raises And to top it all off - No product to offer investors. | putinaire | |
07/12/2024 21:26 | The 'forecasts' must not be very robust given the terminology | putinaire | |
07/12/2024 21:25 | 'Anticipate' - so no assurance of no return to market to raise cash then | putinaire | |
07/12/2024 21:24 | Management therefore anticipates that no further raises for working capital will be required. Following the meetings with Croda, management can confirm that revenues will be received before year end. How do revenues assure no raise required? Don't you mean net operational profits? | putinaire | |
07/12/2024 21:23 | Based on management's baseline expectations for sales under the Croda agreement...... and new sources of revenue from recent acquisitions, Dermatonics and Bio-Tech Solutions, management expects to be cash flow positive from FY2025 Do you expect to be cash positive from the Croda agreement alone? | putinaire | |
07/12/2024 21:19 | Under the terms of the agreement, all details about formulation, functionality and Croda's financial expectations remain confidential due to the competitiveness of the cosmetics market LOOOOOL | putinaire | |
07/12/2024 21:18 | Croda's roll-out and forecasts expected to remain confidential given sensitivity prior to launch LOOOOOOOL TCG on steroids | putinaire |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions